The Use of Continuous Wound Infusion Analgesia in Total Knee Arthroplasty
NCT ID: NCT00724074
Last Updated: 2008-07-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
20 participants
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Hypotheses:
Primary:
The On-Q PainBuster (continuous wound infusion analgesia) in TKA will result in improved patient pain control, compared to usual care.
Secondary:
* Pain scores post-operatively will be better than usual care.
* Fewer narcotics will be ingested post-operatively than with usual care.
* Post-op nausea and vomiting will be less than usual care.
* Length of stay will be shorter compared to usual care.
* Patient satisfaction will be greater than satisfaction with usual care.
* Post-operative infection rates will be no different between groups.
* Fall rates will be no different between groups.
* Subjects will participate in physical therapy the day of surgery.
* Nursing Intensity requirements will be less with the wound infusion due to fewer requests for pain medication.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
S
Patients receive the On-Q local continuous wound infusion system intra-operatively and use it for up to three days post-operatively.
On-Q PainBuster with Bupivacaine
On-Q PainBuster continuous wound infusion analgesia system, using bupivacaine as the local anaesthetic
C
Usual care - post operative pain medications as per the knee arthroplasty care map.
Usual Care
Usual Care
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
On-Q PainBuster with Bupivacaine
On-Q PainBuster continuous wound infusion analgesia system, using bupivacaine as the local anaesthetic
Usual Care
Usual Care
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient of Dr. Arnett
* Deemed fit for continuous wound infusion (no allergies to Bupivacaine or related medications) by anesthesia
* Cognitively aware, and provides informed consent
* Elective (not trauma-related) surgery
* Able to read, speak and understand English
* Adult \< 70 years of age
* Intra-operative spinal anaesthesia
* Reside within metropolitan Edmonton, in a bungalow
* Have a caregiver at home
* ASA risk classification of 1 or 2
* Do not regularly use opioid medication pre-operatively
* Have preoperative knee range of motion \> 90 degrees
* Body Mass Index \< 40
* No known hepatic or liver insufficiency
Exclusion Criteria
18 Years
69 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Capital Health, Canada
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Capital Health
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gordon Arnett, MD
Role: PRINCIPAL_INVESTIGATOR
Capital Health, Canada
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Royal Alexandra Hospital
Edmonton, Alberta, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
garnett
Identifier Type: -
Identifier Source: org_study_id